BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 16391848)

  • 1. Prostate-specific antigen-reactive cytotoxic T lymphocyte precursors in colon cancer patients.
    Wang Y; Harada M; Yano H; Ogasawara S; Tanaka M; Yamada A; Itoh K
    Oncol Rep; 2006 Feb; 15(2):317-21. PubMed ID: 16391848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone-related protein as a common target molecule in specific immunotherapy for a wide variety of tumor types.
    Arima Y; Matsueda S; Yano H; Harada M; Itoh K
    Int J Oncol; 2005 Oct; 27(4):981-8. PubMed ID: 16142314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two proliferation-related proteins, TYMS and PGK1, could be new cytotoxic T lymphocyte-directed tumor-associated antigens of HLA-A2+ colon cancer.
    Shichijo S; Azuma K; Komatsu N; Ito M; Maeda Y; Ishihara Y; Itoh K
    Clin Cancer Res; 2004 Sep; 10(17):5828-36. PubMed ID: 15355913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen-derived epitopes capable of inducing cellular and humoral responses in HLA-A24+ prostate cancer patients.
    Harada M; Kobayashi K; Matsueda S; Nakagawa M; Noguchi M; Itoh K
    Prostate; 2003 Oct; 57(2):152-9. PubMed ID: 12949939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E; Williams PE; Kynaston H; Rowbottom AW
    Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of Tc2 cells with specificity for prostate-specific antigen from patients with hormone-refractory prostate cancer.
    Perambakam S; Xue BH; Sosman JA; Peace DJ
    Cancer Immunol Immunother; 2002 Jul; 51(5):263-70. PubMed ID: 12070713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ran, a small GTPase gene, encodes cytotoxic T lymphocyte (CTL) epitopes capable of inducing HLA-A33-restricted and tumor-reactive CTLs in cancer patients.
    Azuma K; Sasada T; Takedatsu H; Shomura H; Koga M; Maeda Y; Yao A; Hirai T; Takabayashi A; Shichijo S; Itoh K
    Clin Cancer Res; 2004 Oct; 10(19):6695-702. PubMed ID: 15475460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrant expression and potency as a cancer immunotherapy target of inhibitor of apoptosis protein family, Livin/ML-IAP in lung cancer.
    Hariu H; Hirohashi Y; Torigoe T; Asanuma H; Hariu M; Tamura Y; Aketa K; Nabeta C; Nakanishi K; Kamiguchi K; Mano Y; Kitamura H; Kobayashi J; Tsukahara T; Shijubo N; Sato N
    Clin Cancer Res; 2005 Feb; 11(3):1000-9. PubMed ID: 15709165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prostate stem cell antigen-derived peptide immunogenic in HLA-A24- prostate cancer patients.
    Matsueda S; Yao A; Ishihara Y; Ogata R; Noguchi M; Itoh K; Harada M
    Prostate; 2004 Aug; 60(3):205-13. PubMed ID: 15176050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
    Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
    Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of antigenic epitopes recognized by Mac-2 binding protein-specific cytotoxic T lymphocytes in an HLA-A24 restricted manner.
    Kontani K; Teramoto K; Ozaki Y; Fujita T; Tezuka N; Sawai S; Watanabe H; Fujino S; Yokomise H; Ohkubo I
    Int J Oncol; 2004 Dec; 25(6):1537-42. PubMed ID: 15547688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of squamous cell carcinoma antigen-derived peptides having the capacity of inducing cancer-reactive CTLs in HLA-A24+ cancer patients.
    Homma S; Harada M; Yano H; Ogasawara S; Shichijo S; Matsueda S; Komatsu N; Shomura H; Maeda Y; Sato Y; Todo S; Itoh K
    Int J Oncol; 2006 Sep; 29(3):577-87. PubMed ID: 16865273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation between CD8+ T cells specific for prostate-specific antigen and level of disease in patients with prostate cancer.
    Elkord E; Rowbottom AW; Kynaston H; Williams PE
    Clin Immunol; 2006 Jul; 120(1):91-8. PubMed ID: 16458609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An HLA-A3-binding prostate acid phosphatase-derived peptide can induce CTLs restricted to HLA-A2 and -A24 alleles.
    Terasaki Y; Shichijo S; Niu Y; Komatsu N; Noguchi M; Todo S; Itoh K
    Cancer Immunol Immunother; 2009 Nov; 58(11):1877-85. PubMed ID: 19330328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination.
    Noguchi M; Kobayashi K; Suetsugu N; Tomiyasu K; Suekane S; Yamada A; Itoh K; Noda S
    Prostate; 2003 Sep; 57(1):80-92. PubMed ID: 12886526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes.
    Makita M; Hiraki A; Azuma T; Tsuboi A; Oka Y; Sugiyama H; Fujita S; Tanimoto M; Harada M; Yasukawa M
    Clin Cancer Res; 2002 Aug; 8(8):2626-31. PubMed ID: 12171894
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a novel tumor-associated antigen, cadherin 3/P-cadherin, as a possible target for immunotherapy of pancreatic, gastric, and colorectal cancers.
    Imai K; Hirata S; Irie A; Senju S; Ikuta Y; Yokomine K; Harao M; Inoue M; Tsunoda T; Nakatsuru S; Nakagawa H; Nakamura Y; Baba H; Nishimura Y
    Clin Cancer Res; 2008 Oct; 14(20):6487-95. PubMed ID: 18927288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HLA-G as a target molecule in specific immunotherapy against renal cell carcinoma.
    Komohara Y; Harada M; Ishihara Y; Suekane S; Noguchi M; Yamada A; Matsuoka K; Itoh K
    Oncol Rep; 2007 Dec; 18(6):1463-8. PubMed ID: 17982631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2+ prostate cancer patients.
    Yao A; Harada M; Matsueda S; Ishihara Y; Shomura H; Takao Y; Noguchi M; Matsuoka K; Hara I; Kamidono S; Itoh K
    Prostate; 2005 Feb; 62(3):233-42. PubMed ID: 15389794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of robust cytotoxic T lymphocytes against prostate specific antigen by transduction of dendritic cells using protein and recombinant adeno-associated virus.
    Mahadevan M; Liu Y; You C; Luo R; You H; Mehta JL; Hermonat PL
    Cancer Immunol Immunother; 2007 Oct; 56(10):1615-24. PubMed ID: 17356843
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.